{ "items": [ "\n\n
\n \n\n \n \n \n \n Awards and Appointments\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n\n \n\n\n
\n \n\n \n11 October 2021
\n \n \n \nThe Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.
\n \n\n \n \n\n \n\n \n \n \n \n Clinical Trials\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n7 October 2021
\n \n \n \nA new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n\n \n\n\n
\n \n\n \n13 September 2021
\n \n \n \nThe BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n25 August 2021
\n \n \n \nThe University has signed an agreement with Sensyne Health to conduct a multi-omics drug discovery research project in asthma. The project will be led by Dr Timothy Hinks and his team at the Nuffield Department of Medicine\u2019s Respiratory Medicine Unit.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n\n \n\n\n
\n \n\n \n12 July 2021
\n \n \n \nThe Oxford-Suzhou Centre for Advanced Research, known as OSCAR, has marked another significant milestone with the launch of OSCAR-Prenetics Innovation and Technology Centre for Advanced Molecular Diagnostics (the OSCAR-Prenetics ITC).
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n\n \n\n\n
\n \n\n \n23 June 2021
\n \n \n \nThe University of Oxford has joined forces with 11 leading universities to create Impact 12, an impact investment fund to support mission-led university ventures.
\n \n\n \n \n\n \n\n \n \n \n \n Events\n \n \n \n \n Innovation\n \n \n\n \n\n\n
\n \n\n \n1 June 2021
\n \n \n \nAre you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Experimental Medicine in Psychiatry.
\n \n\n \n \n\n \n\n \n \n \n \n Awards and Appointments\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n18 March 2021
\n \n \n \nAssociate Professor Andi Roy leads one of the five research teams across the UK that have been awarded the 2021 Cancer Research UK-Children with Cancer UK Innovation Award. The awards, which provide a total of \u00a34.3 million in scientific funding, will allow leading researchers in the field to delve into the biology of children\u2019s and young people\u2019s cancers, with the hope of finding new ways to prevent and treat these complex cancers.
\n \n\n \n \n\n \n\n \n \n \n \n Awards and Appointments\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n5 March 2021
\n \n \n \nProfessor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce\u2019 (RSA) Albert Medal for her work on the Oxford vaccine.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n25 February 2021
\n \n \n \nSingula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body\u2019s own immune system to fight previously fatal cancers.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n\n \n\n\n
\n \n\n \n16 February 2021
\n \n \n \nThe University of Oxford announced today that it has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n\n \n\n\n
\n \n\n \n4 February 2021
\n \n \n \nEnara Bio, a start-up located in the University\u2019s BioEsclator, has announced a strategic collaboration and licensing agreement with Boehringer Ingelheim, worth over \u20ac876M (\u00a3787M), to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n21 January 2021
\n \n \n \nA partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.
\n \n\n \n \n\n \n\n \n \n \n \n Awards and Appointments\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n\n \n\n\n
\n \n\n \n19 January 2021
\n \n \n \nA new state of the art institute for antimicrobial research is to open at Oxford University thanks to a \u00a3100 million donation from Ineos.
\n \n\n \n \n\n \n\n \n \n \n \n Awards and Appointments\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n\n \n\n\n
\n \n\n \n9 December 2020
\n \n \n \nPepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company\u2019s original seed investor.
\n \n\n \n \n\n \n\n \n \n \n \n Awards and Appointments\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n\n \n\n\n
\n \n\n \n9 December 2020
\n \n \n \nFive new Oxford-Bristol Myers Squibb Fellowships representing an investment of \u00a33M have been announced today*. The fellowships (formerly Oxford-Celgene) will support postdoctoral researchers and clinicians across five departments within the Medical Sciences Division and the Mathematical, Physical and Life Sciences Division, providing an opportunity for them to gain exposure to the field of commercial drug discovery and development.
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n\n \n\n\n
\n \n\n \n18 November 2020
\n \n \n \nCollaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases
\n \n\n \n \n\n \n\n \n \n \n \n General\n \n \n \n \n Innovation\n \n \n\n \n\n\n
\n \n\n \n4 November 2020
\n \n \n \nOxford Sciences Innovation (OSI) recently announced the acquisition of its portfolio company, Base Genomics, by US-based early cancer diagnostic leaders, Exact Sciences, for $410m. The partnership will enable Base Genomics to significantly accelerate its clinical and commercial development here in Oxford, potentially unlocking a new era of preventative medicine and improved patient outcomes.
\n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n Innovation\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n29 October 2020
\n \n \n \n\n \n \n\n \n\n \n \n \n \n Coronavirus COVID-19\n \n \n \n \n Innovation\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n28 September 2020
\n \n \n \nNew research shows that, in a head-to-head comparison of five tests used to detect COVID-19 antibodies (known as \u2018immunoassays\u2019), an assay manufactured by Siemens and one developed by an academic partnership led by the University of Oxford had the most accurate results. The study is published in The Lancet Infectious Diseases.
\n \n\n \n \n